NeoGenomics, Inc. (NEO)
NASDAQ: NEO · Real-Time Price · USD
15.41
-0.61 (-3.81%)
Nov 16, 2026, 4:00 PM EST - Market closed

NeoGenomics Statistics

Total Valuation

NeoGenomics has a market cap or net worth of $1.99 billion. The enterprise value is $2.30 billion.

Market Cap1.99B
Enterprise Value 2.30B

Important Dates

The last earnings date was Wednesday, October 28, 2026, after market close.

Earnings Date Oct 28, 2026
Ex-Dividend Date n/a

Share Statistics

NeoGenomics has 129.39 million shares outstanding. The number of shares has increased by 1.00% in one year.

Current Share Class 129.39M
Shares Outstanding 129.39M
Shares Change (YoY) +1.00%
Shares Change (QoQ) -1.72%
Owned by Insiders (%) 2.14%
Owned by Institutions (%) 109.11%
Float 117.92M

Valuation Ratios

PE Ratio n/a
Forward PE 54.15
PS Ratio 2.53
Forward PS 2.30
PB Ratio 2.49
P/TBV Ratio 153.25
P/FCF Ratio n/a
P/OCF Ratio 466.01
PEG Ratio 0.94
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 2.93
EV / EBITDA 101.23
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 3.53, with a Debt / Equity ratio of 0.56.

Current Ratio 3.53
Quick Ratio 3.04
Debt / Equity 0.56
Debt / EBITDA 14.64
Debt / FCF n/a
Interest Coverage -13.29

Financial Efficiency

Return on equity (ROE) is -3.94% and return on invested capital (ROIC) is -3.92%.

Return on Equity (ROE) -3.94%
Return on Assets (ROA) -1.96%
Return on Invested Capital (ROIC) -3.92%
Return on Capital Employed (ROCE) -3.42%
Weighted Average Cost of Capital (WACC) 11.81%
Revenue Per Employee $315,101
Profits Per Employee -$12,918
Employee Count2,500
Asset Turnover 0.57
Inventory Turnover 16.13

Taxes

Income Tax -3.88M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +49.03% in the last 52 weeks. The beta is 1.83, so NeoGenomics's price volatility has been higher than the market average.

Beta (5Y) 1.83
52-Week Price Change +49.03%
50-Day Moving Average 17.51
200-Day Moving Average 13.01
Relative Strength Index (RSI) 37.89
Average Volume (20 Days) 1,752,953

Short Selling Information

The latest short interest is 13.13 million, so 10.15% of the outstanding shares have been sold short.

Short Interest 13.13M
Short Previous Month 14.22M
Short % of Shares Out 10.15%
Short % of Float 11.14%
Short Ratio (days to cover) 5.94

Income Statement

In the last 12 months, NeoGenomics had revenue of $787.75 million and -$32.30 million in losses. Loss per share was -$0.25.

Revenue787.75M
Gross Profit 352.67M
Operating Income -43.13M
Pretax Income -36.18M
Net Income -32.30M
EBITDA 22.76M
EBIT -43.13M
Loss Per Share -$0.25
Full Income Statement

Balance Sheet

The company has $139.28 million in cash and $449.14 million in debt, with a net cash position of -$309.86 million or -$2.39 per share.

Cash & Cash Equivalents 139.28M
Total Debt 449.14M
Net Cash -309.86M
Net Cash Per Share -$2.39
Equity (Book Value) 800.64M
Book Value Per Share 6.20
Working Capital 293.91M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $4.28 million and capital expenditures -$32.86 million, giving a free cash flow of -$28.58 million.

Operating Cash Flow 4.28M
Capital Expenditures -32.86M
Depreciation & Amortization 65.89M
Net Borrowing 42.09M
Free Cash Flow -28.58M
FCF Per Share -$0.22
Full Cash Flow Statement

Margins

Gross margin is 44.77%, with operating and profit margins of -5.47% and -4.10%.

Gross Margin 44.77%
Operating Margin -5.47%
Pretax Margin -4.59%
Profit Margin -4.10%
EBITDA Margin 2.89%
EBIT Margin -5.47%
FCF Margin n/a

Dividends & Yields

NeoGenomics does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -1.00%
Shareholder Yield -1.00%
Earnings Yield -1.62%
FCF Yield -1.43%

Analyst Forecast

The average price target for NeoGenomics is $23.40, which is 51.85% higher than the current price. The consensus rating is "Buy".

Price Target $23.40
Price Target Difference 51.85%
Analyst Consensus Buy
Analyst Count 11
Revenue Growth Forecast (3Y) 10.05%
EPS Growth Forecast (3Y) 50.79%
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Stock Splits

The last stock split was on April 16, 2003. It was a reverse split with a ratio of 1:100.

Last Split Date Apr 16, 2003
Split Type Reverse
Split Ratio 1:100

Scores

NeoGenomics has an Altman Z-Score of 1.86 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 1.86
Piotroski F-Score 4